Arena Pharmaceuticals Inc. (ARNA)

48.92
0.39 0.79
NASDAQ : Health Technology
Prev Close 49.31
Open 49.92
Day Low/High 48.72 / 50.09
52 Wk Low/High 31.97 / 64.48
Volume 324.98K
Avg Volume 447.70K
Exchange NASDAQ
Shares Outstanding 49.83M
Market Cap 2.44B
EPS -0.60
P/E Ratio 4.19
Div & Yield N.A. (N.A)

Latest News

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc.

A Casket Maker, a File Sharing Company and Other Stocks That Look Good Short

HI, DBX, AVT, SSTI and ARNA all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMPH, KRNT, KTCC, SAFE, SEDG Downgrades: ARNA, CRCM, EPC, IIPR, RGR, RYN, SCWX, SSTI, VCRA Initiations: EPRT, EVER, GSKY, INSP Read on to get TheStreet Quant Ratings' detailed report:

Arena Reports Second Quarter Financial Results With Strong Liquidity Position, And Initiation Of Etrasimod ELEVATE UC 52 And Olorinab CAPTIVATE Trials

Arena Reports Second Quarter Financial Results With Strong Liquidity Position, And Initiation Of Etrasimod ELEVATE UC 52 And Olorinab CAPTIVATE Trials

- Etrasimod initiation of the Phase 3 ELEVATE UC 52 global trial in ulcerative colitis (UC)

Arena Pharmaceuticals To Release Second Quarter 2019 Financial Results And Provide Corporate Update On August 7

Arena Pharmaceuticals To Release Second Quarter 2019 Financial Results And Provide Corporate Update On August 7

SAN DIEGO, July 31, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its second quarter 2019 financial results and provide a corporate update on Wednesday, August 7, 2019, after the close of the U.

Arena Pharmaceuticals Announces First Subject Dosed In ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod In Ulcerative Colitis

Arena Pharmaceuticals Announces First Subject Dosed In ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod In Ulcerative Colitis

- Significant unmet need for new effective therapies exists in ulcerative colitis

Arena Pharmaceuticals To Present At JMP Securities Life Sciences Conference On June 19

Arena Pharmaceuticals To Present At JMP Securities Life Sciences Conference On June 19

SAN DIEGO, June 13, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARNA, CELH, CIR, DGICB Downgrades: BBW, CNNE, COOP, EVI, GHL, HTBI, HVT, IMMR, LEG, NOV, NPK, PLCE, SHO, SOI, VMI, WB Initiations: AGS Read on to get TheStreet Quant Ratings' detailed report:

Corvidia Therapeutics Announces Dr. Preston Klassen Joins Its Board Of Directors

Corvidia Therapeutics Announces Dr. Preston Klassen Joins Its Board Of Directors

WALTHAM, Mass., May 21, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc.

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Rally or Selloff?: Cramer's 'Mad Money' Recap (Friday 5/17/19)

Jim Cramer says we'll need to pay close attention to retailers' earnings. Here's your game plan for next week.

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Arena Pharmaceuticals, DaVita, Merck: 'Mad Money' Lightning Round

Jim Cramer weighs in on Arena Pharmaceuticals, DaVita, Merck, Abbott Laboratories, IAC Interactive, Yext and more.

Chart of the Day: Arena Pharmaceuticals

Biotech stock Arena is flexing its muscles.

June 28th Options Now Available For Arena Pharmaceuticals (ARNA)

June 28th Options Now Available For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the June 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new June 28th contracts and identified the following put contract of particular interest.

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

Arena Pharmaceuticals To Participate In Upcoming Investor Conferences

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20, at...

Arena Pharmaceuticals Provides Corporate Update And Reports First Quarter 2019 Financial Results

Arena Pharmaceuticals Provides Corporate Update And Reports First Quarter 2019 Financial Results

- Etrasimod ELEVATE UC Phase 3 Program expected to initiate mid-year targeting significant unmet need in ulcerative colitis

Arena Pharmaceuticals To Release First Quarter 2019 Financial Results And Provide Corporate Update On May 8

Arena Pharmaceuticals To Release First Quarter 2019 Financial Results And Provide Corporate Update On May 8

SAN DIEGO, May 1, 2019 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2019 financial results and provide a corporate update on Wednesday, May 8, 2019, after the close of the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARNA, CNTY, GPOR Downgrades: FRPT, JW.A, JW.B, NL, WSR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Putting the Markets in Focus: Cramer's 'Mad Money' Recap (Thursday 11/15/18)

Jim Cramer says perception is determining how stocks trade right now -- and there's a lot of negativity.

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

BP, Arconic, Fiat Chrysler: 'Mad Money' Lightning Round

Jim Cramer take a closer look at BP, Arconic, Fiat Chrysler, Qualcomm, Thermo Fisher, GameStop, Arena Pharmaceuticals and more.

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Arena Pharmaceuticals: Don't Fight the Tape or Jim Cramer's Evaluation

Let's see what the charts suggest for risk points.

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Gridlock and Economic Slowing: Cramer's 'Mad Money' Recap (Tuesday 11/6/18)

Jim Cramer explains his post-election play book: Growth stocks may be the way to go.

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Canada Goose, Celgene, BlackRock: 'Mad Money' Lightning Round

Jim Cramer weighs in on Canada Goose, Celgene, BlackRock, Nio, Hospitality Property Trust, Activision Blizzard and more.

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

First Week Of September 21st Options Trading For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 86 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Sector Steps Up to Provide Some Strong Action for Traders

Biotech Sector Steps Up to Provide Some Strong Action for Traders

The S&P 500 has shown the same pattern for three consecutive days.

TheStreet Quant Rating: C+ (Hold)